Maris JM - Search Results

1

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Matthay KK, et al. Among authors: maris jm. J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171714 Free PMC article. Clinical Trial.

2

Molecular biology of neuroblastoma.

Maris JM, Matthay KK. Maris JM, et al. J Clin Oncol. 1999 Jul;17(7):2264-79. doi: 10.1200/JCO.1999.17.7.2264. J Clin Oncol. 1999. PMID: 10561284 Review.

3

Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.

Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Maris JM, et al. J Clin Oncol. 2000 May;18(9):1888-99. doi: 10.1200/JCO.2000.18.9.1888. J Clin Oncol. 2000. PMID: 10784629

4

Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.

Shusterman S, Grupp SA, Maris JM. Shusterman S, et al. Among authors: maris jm. Med Pediatr Oncol. 2000 Dec;35(6):673-6. doi: 10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o. Med Pediatr Oncol. 2000. PMID: 11107144

5

The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.

Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. Shusterman S, et al. Among authors: maris jm. Clin Cancer Res. 2001 Apr;7(4):977-84. Clin Cancer Res. 2001. PMID: 11309349

6

Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.

Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM. Maris JM, et al. Med Pediatr Oncol. 2001 Jan;36(1):24-7. doi: 10.1002/1096-911X(20010101)36:1<24::AID-MPO1007>3.0.CO;2-7. Med Pediatr Oncol. 2001. PMID: 11464895

7

Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM. Kang TI, et al. Among authors: maris jm. J Pediatr Hematol Oncol. 2003 Oct;25(10):769-73. doi: 10.1097/00043426-200310000-00005. J Pediatr Hematol Oncol. 2003. PMID: 14528098

8

Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma.

Hickeson MP, Charron M, Maris JM, Brophy P, Kang TI, Zhuang H, Khan J, Nevrotski T. Hickeson MP, et al. Among authors: maris jm. Pediatr Blood Cancer. 2004 Mar;42(3):268-74. doi: 10.1002/pbc.10454. Pediatr Blood Cancer. 2004. PMID: 14752865

9

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.

DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK. DuBois SG, et al. Among authors: maris jm. J Clin Oncol. 2004 Jun 15;22(12):2452-60. doi: 10.1200/JCO.2004.08.058. J Clin Oncol. 2004. PMID: 15197208 Clinical Trial.

10

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.

Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA, Matthay KK. Howard JP, et al. Among authors: maris jm. Pediatr Blood Cancer. 2005 Mar;44(3):232-9. doi: 10.1002/pbc.20240. Pediatr Blood Cancer. 2005. PMID: 15490487

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

468 results

Search Page

Filters